Guiheen Lawrence P.'s Form 4 filing
Adma Biologics, Inc. (ADMA) · filed Sep 11, 2024
- Accession no.
- 0001140361-24-040872
- Filed
- Sep 11, 2024
- Trade date
- Sep 9, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $166.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Guiheen Lawrence P.CIK 0001554353 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Common Stock | MOption exerciseAcquired | +9,000 | $10.80 | +$97,200 | 162,941 | Direct | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −9,000 | $18.47 | −$166,230 | 153,941 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Common Stock | MOption exerciseDisposed | −9,000 | $10.80 | −$97,200 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.